GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDNL.L Share News (DNL)

  • There is currently no data for DNL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Polar Capital Global Healthcare Lags Behind Benchmark In First Half

Fri, 10th May 2019 09:36

LONDON (Alliance News) - Polar Capital Global Healthcare Trust PLC said on Friday it lagged against its benchmark for the first half of its financial year, as the healthcare trust underperformed in the period.

For the six months to the end of March, the trust's net asset value negative return was 3.0%, compared to the 2.3% negative return by the MSCI ACWI/Healthcare Index in sterling terms, with dividends reinvested.

Net asset value per share as at March 31 was 233.53 pence, up from 183.00p the same date the year before, but down from 241.91p at the end of September.

Polar Capital's share price at the end of March was 216.00p, reflecting a discount to net asset value of 7.5%, widened from 6.1% the year before.

Shares in Polar Capital Global Healthcare were down 1.0% on the day Friday at 203.50 pence, having fallen 5.8% since the period-end.

The trust said that the overall healthcare market "modestly underperformed", with major sell-offs in October and December due to trade friction, slowing global growth, as well as political uncertainties.

Detractors within the trust's portfolio includes Diurnal Group PLC, which reported that its congenital adrenal hyperplasia treatment product Chronocort failed to meet its primary objective in its phase three trial.

Another detractor was Consort Medical PLC, due to delays in some of its customer projects.

However, stocks that performed well were Merck & Co Inc, with strong momentum in its immuno-oncology and vaccines businesses, and Renalytix AI PLC, due to progress in the development of its AI-enabled product for treating kidney diseases.

"While backward looking, the temperamental, almost nervous nature of the market further underpins our view that large-cap healthcare companies should be a relatively attractive place to invest in the near to medium term," Polar Capital Global Healthcare said.

"With technology at the fore, we continue to believe we can find companies within our investment universe that are capable of delivering mid to high single-digit, organic, top-line growth, operating leverage as well as high single to low double-digit total shareholder returns," the trust added.

More News
13 Nov 2020 16:06

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
28 Oct 2020 19:08

IN BRIEF: Diurnal Taps Investors For GBP9.8 Million

IN BRIEF: Diurnal Taps Investors For GBP9.8 Million

Read more
21 Oct 2020 21:15

IN BRIEF: Diurnal's Swiss Partner Seeks Marketing Approval For Alkindi

IN BRIEF: Diurnal's Swiss Partner Seeks Marketing Approval For Alkindi

Read more
21 Oct 2020 15:40

Diurnal up as its partner advances Swiss authorisation for 'Alkindi'

(Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced on Wednesday that its marketing and distribution partner in Switzerland, EffRx Pharmaceuticals, has submitted a market authorisation application to Swissmedic for the registration of 'Alkindi', or hydrocortisone granules in capsules for opening, in the country.

Read more
9 Oct 2020 16:13

Diurnal raising up to £10m in placing and open offer

(Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced a proposed conditional placing with institutional investors to raise up to £8m before expenses on Friday, at a price of 60p per share, and an open offer to raise up to a further £2m.

Read more
9 Oct 2020 11:56

Diurnal Raises GBP8 Million For Product Development, Commercialisation

Diurnal Raises GBP8 Million For Product Development, Commercialisation

Read more
30 Sep 2020 14:28

IN BRIEF: Diurnal Gets US FDA Approval For Alkindi Sprinkle

IN BRIEF: Diurnal Gets US FDA Approval For Alkindi Sprinkle

Read more
15 Sep 2020 16:01

IN BRIEF: Diurnal Annual Revenue Climbs And Loss Narrows

IN BRIEF: Diurnal Annual Revenue Climbs And Loss Narrows

Read more
14 Sep 2020 13:13

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

IN BRIEF: Cambridge Cognition Hires Diurnal CFO Bungay As Non-Exec

Read more
8 Sep 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
3 Sep 2020 14:04

IN BRIEF: Diurnal Inks Two European Marketing And Distribution Pacts

IN BRIEF: Diurnal Inks Two European Marketing And Distribution Pacts

Read more
3 Sep 2020 11:35

Diurnal signs two new distribution agreements in Europe

(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced two further European market and distribution agreements for its products 'Alkindi', or hydrocortisone granules in capsules for opening, and 'Chronocort', or modified release hydrocortisone, on Thursday.

Read more
10 Aug 2020 11:10

IN BRIEF: Australian Regulator Approves Diurnal Drug Alkindi

IN BRIEF: Australian Regulator Approves Diurnal Drug Alkindi

Read more
5 Aug 2020 19:16

UK TRADING UPDATE SUMMARY: Regional REIT Valuation Dips In First Half

UK TRADING UPDATE SUMMARY: Regional REIT Valuation Dips In First Half

Read more
26 May 2020 17:50

Clinigen Chair Leaves Audit Committee After Shareholder Engagement

Clinigen Chair Leaves Audit Committee After Shareholder Engagement

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.